Crohn's Disease Activity Index

titled Therapy of Active Crohn Disease with Boswellia Serrata Extract H15 randomized 102 patients into either a Boswellia group or mesalazine group.

Instead of the outcome being remission, they use the CDAI or Crohn's disease activity index, which runs from zero to 600 with higher scores, obviously meaning greater disease activity.

The CDAI of the Boswellia group was reduced by 90 points, while the mesalazine group was only reduced by 53 points.

That's a pretty big difference.

The authors conclude, quote, considering both safety and efficacy of Boswellia serrata extract H15, it appears to be superior over mesalazine in terms of a benefit-risk evaluation, end quote.

Yeah, so again, this is a term typically that we use in clinical trials, right? And so clinical remission, endoscopic remission, these are terms that usually have set definitions that are typically based around scores, right? So in ulcerative colitis, we use things like the Mayo score.

In Crohn's disease, we use the CDAI score.

These are just scores that we don't typically use in the clinic.

But just so everybody is aware, these are sort of clinical trial tools that we use.